» Authors » Marina Mitjans

Marina Mitjans

Explore the profile of Marina Mitjans including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 47
Citations 1694
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Koller D, Lokhammer S, Goroshchuk O, Denner V, Stiltner B, Mitjans M, et al.
JAMA Psychiatry . 2025 Feb; PMID: 39908042
Importance: Although psychological traumas have been associated with endometriosis, limited information is available regarding the role of trauma type and genetic predisposition. Objective: To examine the relationship between traumatic experiences...
2.
Mitjans M, Papiol S, Fatjo-Vilas M, Gonzalez-Penas J, Acosta-Diez M, Zafrilla-Lopez M, et al.
Eur Neuropsychopharmacol . 2024 Jun; 86:49-54. PMID: 38941950
Evidence suggests a remarkable shared genetic susceptibility between psychiatric disorders. However, sex-dependent differences have been less studied. We explored the contribution of schizophrenia (SCZ), bipolar disorder (BD) and major depressive...
3.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Int J Bipolar Disord . 2024 Jun; 12(1):20. PMID: 38865039
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
4.
Zafrilla-Lopez M, Acosta-Diez M, Mitjans M, Gimenez-Palomo A, Saiz P, Barrot-Feixat C, et al.
Eur Neuropsychopharmacol . 2024 Apr; 85:23-31. PMID: 38669938
Lithium (Li) is the first-line treatment for bipolar disorder (BD) even though only 30 % of BD patients are considered excellent responders. The mechanisms by which Li exerts its action...
5.
Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, Alda M, et al.
Transl Psychiatry . 2024 Feb; 14(1):109. PMID: 38395906
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
6.
Koller D, Mitjans M, Kouakou M, Friligkou E, Cabrera-Mendoza B, Deak J, et al.
Psychiatry Res . 2024 Feb; 333:115758. PMID: 38335780
We characterized the genetic architecture of the attention-deficit hyperactivity disorder-substance use disorder (ADHD-SUD) relationship by investigating genetic correlation, causality, pleiotropy, and common polygenic risk. Summary statistics from genome-wide association studies...
7.
Herrera-Rivero M, Adli M, Akiyama K, Akula N, Amare A, Ardau R, et al.
Res Sq . 2023 Dec; PMID: 38077040
Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP....
8.
Kelsoe J, Ou A, Rosenthal S, Adli M, Akiyama K, Akula N, et al.
Res Sq . 2023 Oct; PMID: 37886563
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
9.
Herrera-Rivero M, Gutierrez-Fragoso K, Thalamuthu A, Amare A, Adli M, Akiyama K, et al.
Res Sq . 2023 Jul; PMID: 37461719
The link between bipolar disorder (BP) and immune dysfunction remains controversial. While epidemiological studies have long suggested an association, recent research has found only limited evidence of such a relationship....
10.
Amare A, Thalamuthu A, Schubert K, Fullerton J, Ahmed M, Hartmann S, et al.
Mol Psychiatry . 2023 Jul; 28(12):5251-5261. PMID: 37433967
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not...